Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Joshua D. Thornton

Josh Thornton is a founding member of the Healthcare practice at Centerview Partners. He is an experienced advisor to senior management teams and boards of public and private life sciences companies. Over the course of his career he has engaged with life sciences clients across biopharma, medical devices, diagnostics and tools on a broad range of complex strategic and financial issues and transactions, including mergers, acquisitions, divestitures, partnerships, defense, and debt and equity financings.

Mr. Thornton’s recent notable transactions include Prometheus Bioscience’s $10.8 billion sale to Merck, MyoKardia’s $13.1 billion sale to Bristol Myers Squibb, AveXis’ $8.7 billion sale to Novartis, Momenta’s $6.5 billion sale to Johnson & Johnson, Global Blood Therapeutics’ $5.8 billion sale to Pfizer, Principia’s $3.7 billion sale to Sanofi, Affinivax’s up to $3.3 billion sale to GSK, Audentes Therapeutics’ $3.0 billion sale to Astellas Pharma, Portola Pharmaceuticals’ $1.6 billion sale to Alexion Pharmaceuticals, Forma Therapeutics’ $1.1 billion sale to Novo Nordisk, Icosavax’s up to $1.1 billion sale to AstraZeneca, Amolyt Pharmaceuticals’ $1.05 billion sale to AstraZeneca, and ViaCyte’s $320 million sale to Vertex.

Other notable transactions include Pfizer’s $68 billion acquisition of Wyeth, InterMune’s $8.9 billion sale to Roche, Receptos’ $7.8 billion sale to Celgene, OSI Pharmaceuticals’ $4.0 billion sale to Astellas Pharma, Thoratec’s $3.7 billion sale to St. Jude Medical, Avanir’s $3.5 billion sale to Otsuka, Biogen Idec’s $3.25+ billion acquisition of full rights and control of Tysabri from Elan, Pacific Biosciences’ $1.3 billion sale to Illumina, MAP Pharmaceuticals’ $958 million sale to Allergan, Bioverativ’s acquisition of True North Therapeutics for up to $825 million, Haemonetics’ $551 million acquisition of assets from Pall Corporation, XenoPort’s $457 million sale to Arbor Pharmaceuticals, Ultragenyx’s $151 million acquisition of Dimension Therapeutics, Dendreon Corporation’s sale of a royalty interest to CPPIB, and Cytokinetics’s sale of a royalty interest to Royalty Pharma.

Mr. Thornton joined Centerview in 2009 from Merrill Lynch where he worked in the Mergers & Acquisitions Group. He holds an M.B.A. from the Stern School of Business at New York University and a B.A. in Economics/East Asian Studies from Wesleyan University.
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Mariana Oncology, Inc.
Announced: Q2 2024
Value: $1.75 billion
Status: Closed

Financial advisor to Mariana on its sale to Novartis
View All
New York

Centerview Partners LLC

31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax

Centerview Partners UK LLP

1 Sherwood Street

6th Floor

London W1F 7BL

02074099700 | Tel
02074099704 | Fax

Centerview Partners France SCS

51 Avenue Hoche

Paris 75008

0180200620 | Tel
0180200621 | Fax
Menlo Park

Centerview Partners LLC

1302 El Camino Real

Suite 350

Menlo Park, California 94025

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC

555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax

Copyright © 2008 - 2024 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC